Transdel Pharmaceuticals to Present at Rodman & Renshaw 10th Annual Global Healthcare Conference
tainty of future financial results additional financing requirementsdevelopment of new products government approval processes the impact ofcompetitive products or pricing technological changes the effect ofeconomic conditions and other uncertainties detailed in the Company'sfilings with the Securities and Exchange Commission.
Date:11/4/2008
tainty of future financial results, additional financing requirements,
development of new products, government approval processes, the impact of
competitive products or pricing, technological changes, the effect of
economic conditions and other uncertainties detailed in the Company's
filings with the Securities and Exchange Commission.
'/>"/>SOURCE Transdel Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 Related biology technology :1.
Transdel Pharmaceuticals Closes $4 Million Financing2.
Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes3.
China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results4.
Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML5.
XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 20076.
Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results7.
Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences8.
Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer9.
Poniard Pharmaceuticals Announces Participation in Upcoming Conferences10.
NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals11.
Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)